Publicaciones en colaboración con investigadores/as de Ludwig Maximilian University of Munich (29)

2023

  1. Increased uptake of the P2X7 receptor radiotracer 18F-JNJ-64413739 in the brain and peripheral organs according to the severity of status epilepticus in male mice

    Epilepsia, Vol. 64, Núm. 2, pp. 511-523

  2. The P2X7 receptor contributes to seizures and inflammation-driven long-lasting brain hyperexcitability following hypoxia in neonatal mice

    British Journal of Pharmacology, Vol. 180, Núm. 13, pp. 1710-1729

2022

  1. Gene signatures in patients with early breast cancer and relapse despite pathologic complete response

    npj Breast Cancer, Vol. 8, Núm. 1

  2. Increased expression of the ATP-gated P2X7 receptor reduces responsiveness to anti-convulsants during status epilepticus in mice

    British Journal of Pharmacology, Vol. 179, Núm. 12, pp. 2986-3006

2021

  1. Circulating p2x7 receptor signaling components as diagnostic biomarkers for temporal lobe epilepsy

    Cells, Vol. 10, Núm. 9

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    Annals of Oncology, Vol. 31, Núm. 12, pp. 1623-1649

  2. Characterization of the Expression of the ATP-Gated P2X7 Receptor Following Status Epilepticus and during Epilepsy Using a P2X7-EGFP Reporter Mouse

    Neuroscience Bulletin, Vol. 36, Núm. 11, pp. 1242-1258

  3. Enhancing global access to cancer medicines

    CA Cancer Journal for Clinicians, Vol. 70, Núm. 2, pp. 105-124

  4. Pembrolizumab for early triple-negative breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 9, pp. 810-821

2018

  1. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1634-1657

  2. Nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic Breast cancer: Results from the tnAcity trial

    Annals of Oncology, Vol. 29, Núm. 8, pp. 1763-1770

2017

  1. Forebrain-specific, conditional silencing of Staufen2 alters synaptic plasticity, learning, and memory in rats

    Genome Biology, Vol. 18, Núm. 1

  2. Live imaging followed by single cell tracking to monitor cell biology and the lineage progression of multiple neural populations

    Journal of Visualized Experiments, Vol. 2017, Núm. 130

  3. Research needs in breast cancer

    Annals of Oncology, Vol. 28, Núm. 2, pp. 208-217

2016

  1. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel

    Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390

  2. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366

  3. Analysis of plasminogen genetic variants in multiple sclerosis patients

    G3: Genes, Genomes, Genetics, Vol. 6, Núm. 7, pp. 2073-2079

  4. Astrocytic Insulin Signaling Couples Brain Glucose Uptake with Nutrient Availability

    Cell, Vol. 166, Núm. 4, pp. 867-880

  5. Erratum to 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): Study protocol for a randomized controlled trial. [Trials (2015), 16, 575] DOI: 10.1186/s13063-016-1195-6

    Trials